

## KEYWORD INDEX (By Abstract No.)

- 90-yttrium, 201, 231, 478  
 ABT-263, 300, 528  
 ABVD, 19, 83, 124, 125, 126, 127, 253, 256, 336, 455, 456, 500, 501, 571  
 activated B-cell-like (ABC), 9, 43, 91, 96, 214, 277, 281, 291, 322, 351, 389  
 ALK, 76, 77, 78, 305  
 allogeneic stem cell transplant (alloSCT), 23, 24, 25, 59, 82, 140, 144, 155, 237, 266, 482, 510, 511  
 anaplastic large cell lymphoma (ALCL), 76, 77, 78, 138, 303, 305, 451, 511, 540, 541  
 angioimmunoblastic T-cell lymphoma (AITL), 95, 152, 153, 184, 185, 450  
 anthracycline, 186, 187, 239, 325, 413  
 antibody-dependent cytotoxicity (ADC), 41, 154, 196, 284, 285, 540, 542  
 apoptosis, 57, 146, 300, 349, 517, 522, 533  
 Ara-C, 45, 415, 416, 417, 420, 568  
 Array-comparative genomic hybridization, 43, 72, 91, 196  
 aurora kinase, 282, 539, 549  
 autologous stem cell transplantation (ASCT), 20, 21, 22, 44, 64, 82, 85, 86, 89, 112, 120, 141, 143, 155, 202, 219, 220, 231, 241, 264, 265, 266, 268, 269, 371, 383, 409, 416, 417, 441, 457, 473, 479, 480, 482, 494, 503, 507, 508, 509, 512, 513, 546  
 B-cell lymphoma, 13, 16, 20, 24, 26, 29, 38, 47, 65, 66, 79, 80, 98, 109, 116, 139, 148, 158, 162, 165, 181, 182, 200, 202, 205, 213, 223, 239, 247, 277, 278, 280, 283, 287, 288, 290, 295, 304, 311, 318, 319, 334, 338, 346, 347, 359, 361, 402, 407, 408, 410, 413, 438, 449, 463, 464, 476, 477, 479, 483, 493, 494, 515, 516, 517, 530, 532, 548, 551  
 B-cell receptor (BCR), 51, 171, 277, 280, 281, 286, 291, 292, 293, 313, 314, 333, 543, 548  
 B-cells, 6, 50, 66, 92, 170, 277, 302, 332, 426, 552  
 BCL2, 6, 57, 73, 146, 164, 178, 179, 193, 210, 282, 300, 317, 329, 338, 339, 368, 523, 528  
 BCL6, 116, 162, 179, 240, 338, 440  
 BEACOPP, 87, 126, 127, 456, 500  
 BEAM, 417, 479, 506, 508  
 bendamustine, 20, 32, 37, 68, 84, 100, 104, 135, 137, 149, 289, 298, 367, 370, 419, 420, 421, 469, 509, 529, 555  
 bleomycin, 501  
 bortezomib, 28, 29, 89, 109, 132, 147, 191, 214, 449, 472, 473, 530, 532, 559  
 brentuximab vedotin, 140, 141, 151, 152, 303, 304, 461, 511, 540, 541, 570, 571  
 bromodomains, 114  
 BTK, 67, 69, 137, 277, 280, 291, 293, 313, 556, 558  
 Burkitt lymphoma (BL), 13, 80, 81, 161, 182, 215, 365, 382, 395, 515, 522  
 Busulfan, 409  
 CAL-101 (GS-1101), 110  
 CD10, 184, 368  
 CD19, 302, 542  
 CD20, 38, 75, 131, 135, 194, 350, 368, 393, 444, 493, 522  
 CD22, 39, 148, 287, 290  
 CD3, 302, 444, 542  
 CD30, 9, 140, 151, 152, 303, 304, 444, 540, 571  
 CD38, 284  
 CD5, 343, 352, 400  
 chemokines, 41, 51, 154, 158, 246, 262  
 chlorambucil, 7, 37, 56, 107, 436, 470  
 chromosomal translocations, 6, 73, 319  
 chronic lymphocytic leukemia (CLL), 8, 25, 37, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 105, 106, 107, 134, 145, 167, 171, 257, 258, 259, 260, 261, 262, 284, 292, 297, 298, 300, 313, 314, 342, 353, 462, 463, 465, 466, 467, 468, 469, 470, 510, 522, 524, 531, 543, 548, 550, 551, 552, 553, 555, 558  
 cladribine, 263  
 classical Hodgkin lymphoma (cHL), 34, 75, 124, 141, 309, 335, 336, 337, 349, 356, 454, 460, 486, 489, 571  
 CNS prophylaxis, 48, 218, 400, 439  
 cutaneous B-cell lymphoma (CBCL), 96  
 cutaneous T-cell lymphoma (CTCL), 41, 94, 279, 294, 355, 443  
 CVP, 88, 190  
 cyclins, 10, 109, 531  
 cyclophosphamide, 257, 267, 412  
 cytogenetics, 80, 259, 314, 329, 344, 391  
 cytokines, 27, 170, 183, 262  
 dacarbazine, 460  
 DA-R-EPOCH, 75, 400  
 Deauville's criteria, 133, 503  
 deep sequencing, 90, 94, 95, 108, 109, 168, 169  
 dendritic cells, 288  
 DHAP, 86, 261, 559  
 diffuse large B-cell lymphoma (DLBCL), 4, 5, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 27, 31, 48, 64, 65, 80, 85, 91, 103, 114, 119, 120, 121, 122, 123, 131, 132, 157, 158, 160, 162, 163, 164, 167, 177, 178, 179, 180, 181, 182, 183, 202, 206, 207, 208, 209, 210, 211, 212, 213, 214, 218, 220, 221, 222, 223, 224, 226, 239, 245, 246, 264, 273, 275, 278, 281, 285, 291, 301, 304, 307, 318, 320, 322, 323, 325, 331, 332, 333, 334, 339, 343, 344, 345, 350, 351, 352, 382, 383, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 396, 397, 398, 400, 401, 402, 404, 405, 406, 408, 409, 411, 412, 413, 414, 426, 430, 433, 434, 435, 475, 480, 485, 487, 495, 496, 497, 514, 527, 537, 549, 559, 560, 568  
 DNA microarrays, 544  
 double-hit lymphomas, 24, 179, 180, 182, 282, 528  
 doxorubicin, 190, 215, 413, 460, 528  
 EBER, 394  
 elderly, 21, 22, 45, 56, 102, 104, 105, 106, 107, 208, 221, 222, 224, 376, 377, 402, 410, 411, 412, 421, 459, 467, 476  
 epigenetics, 115, 167, 172, 283  
 EPOCH, 5  
 Epstein-Barr virus (EBV), 9, 166, 216, 217, 332, 340, 364, 394  
 ERK, 263  
 ESHAP, 261, 448  
 etiology principles, 73, 205  
 etoposide, 412  
 expression arrays, 26, 287, 313  
 extranodal lymphomas, 2, 47, 48, 70, 98, 235, 243, 340, 385, 425, 427, 428, 429, 432, 452, 454, 481  
 extranodal marginal zone lymphoma of MALT type, 100, 101, 251, 434, 435  
 EZH2, 115, 172, 533  
 F-18-fluorodeoxyglucose (FDG), 17, 124, 272, 335, 486, 500, 502  
 flow cytometry, 171, 174, 175, 314, 329, 331, 341  
 fludarabine, 37, 105, 106, 107, 192, 260, 371, 373, 381, 468, 550  
 fluorescence in situ hybridization (FISH), 12, 96, 177, 210  
 follicular lymphoma (FL), 2, 6, 13, 60, 61, 62, 63, 72, 73, 74, 102, 104, 115, 117, 136, 149, 156, 159, 164, 169, 172, 173, 176, 186, 187, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 271, 273, 284, 301, 317, 318, 329, 367, 368, 369, 371, 374, 375, 376, 377, 378, 379, 380, 429, 474, 491, 492, 504, 507, 509, 523, 529, 547, 549, 556, 561, 562, 563  
 GCB lymphoma subtype, 116, 213, 323, 351  
 gemcitabine, 64, 85, 407, 416, 449, 565  
 gene expression profile (GEP), 10, 11, 12, 27, 75, 90, 91, 132, 156, 157, 259, 323, 388, 525, 545  
 gene rearrangement, 12, 96  
 germinal center (GC), 6, 311, 339  
 germinal center B cell-like (GCB), 91, 115, 264  
 graft-versus-lymphoma, 23  
 GVHD, 23  
 hepatitis B, 358  
 hepatitis C, 188, 359, 363, 396  
 high-dose steroids, 362  
 high-dose therapy (HDT), 120, 142, 238, 241, 416, 506  
 highly active anti-retroviral therapy (HAART), 365, 382  
 histone deacetylase inhibitors, 29, 116, 117, 118, 153, 283, 450, 569  
 Hodgkin lymphoma (HL), 18, 19, 30, 33, 35, 36, 42, 87, 92, 125, 126, 127, 128, 139, 140, 142, 143, 144, 166, 170, 225, 252, 253, 254, 255, 268, 270, 274, 275, 276, 301, 303, 312, 324, 407, 439, 454, 455, 456, 457, 458, 459, 460, 483, 487, 498, 500, 501, 502, 503, 511, 512, 540, 541, 569  
 human immunodeficiency virus (HIV), 365, 382  
 human T-lymphotropic virus (HTLV), 23, 154  
 hyper-CVAD, 403  
 hypergammaglobulinemia, 326, 327  
 ibritumomab tiuxetan, 201, 406, 476, 477, 480  
 ibrutinib, 28, 51, 67, 69, 137, 262, 292, 293, 556, 557, 562  
 ICE, 16, 44, 141  
 ifosfamide, 407  
 IGEV, 19, 142, 502, 569  
 immune system, 159, 176, 233, 314, 346  
 immunochemotherapy, 74, 183, 187, 194, 211, 226, 288, 358, 369, 370, 374, 375, 377, 380, 395, 469, 493, 546, 547, 561, 568  
 immunodeficiency-associated lymphomas, 365  
 immunoglobulins (Ig), 49, 108, 169, 227, 320, 326, 327, 339, 381, 529  
 immunohistochemistry (IHC), 173, 178, 180, 181, 210, 214, 278, 287, 328, 334, 335, 339, 340, 348, 351  
 immunomodulators (IMiDs), 113, 536  
 immunophenotype, 176, 227, 288, 464  
 immunosuppression, 159, 160, 267, 288, 358, 362, 366, 381  
 immunotoxins, 290  
 indolent lymphoma, 32, 68, 73, 88, 135, 191, 202, 227, 233, 251, 266, 296, 363, 369, 370, 373, 381, 487, 510, 548, 551, 554  
 induction treatment, 32, 187, 199, 380, 492

- inotuzumab ozogamicin, 148, 290  
 interferon (INF), 170, 363, 442  
 interleukines, 342, 472, 546  
 JAK/STAT, 94, 240, 252  
 Ki-67, 10, 17, 51  
 L-asparaginase, 99, 235, 236, 537  
 lenalidomide, 43, 58, 63, 134, 136, 213, 251, 260, 289, 299, 450, 460, 518, 530, 562, 563  
 lymphoblastic lymphoma (LBL), 403  
 lymphoplasmacytic lymphoma/  
 Waldenstroem (LPL/WM), 175  
 macrophages, 156, 157, 158, 166, 331, 335, 336, 337, 486  
 magnetic resonance imaging (MRI), 275, 488, 489, 505  
 MALT1, 31, 163  
 mantle cell lymphoma (MCL), 2, 29, 84, 86, 89, 90, 108, 109, 110, 111, 112, 114, 117, 137, 146, 147, 149, 227, 228, 229, 230, 231, 245, 284, 293, 295, 299, 319, 378, 408, 415, 416, 417, 418, 419, 420, 421, 434, 487, 515, 518, 529, 532, 533, 534, 557  
 marginal zone lymphoma (MZL), 7, 101, 174, 200, 203, 250, 341, 422, 423, 431, 561  
 methotrexate (MTX), 45, 247, 248, 310, 400, 437, 440, 528, 568  
 microRNA, 50, 54, 166, 181, 244, 245, 312, 324, 342, 345  
 minimal residual disease (MRD), 106, 108, 197, 198, 230, 258, 369  
 mitoxantrone, 186  
 molecular genetics, 49, 54, 81, 169, 172, 196, 316, 444, 523  
 monoclonal antibodies (MoAb), 38, 41, 152, 154, 195, 304, 306, 348, 542, 570  
 monoclonal B-cell lymphocytosis (MBL), 2  
 monoclonality, 388  
 monomethyl auristatin E, 287  
 mouse models, 27, 77, 92, 113, 158, 161, 311, 319, 514, 515, 527  
 mTor inhibitors, 46, 149, 250, 537, 560  
 Mucosa-Associated Lymphoid Tissue (MALT), 7, 101, 436  
 multiple myeloma (MM), 28, 204, 471, 472, 473, 490, 505, 545  
 MYC, 12, 30, 80, 113, 114, 162, 177, 178, 179, 181, 282, 311, 317, 338, 527, 537  
 mycosis fungoides (MF), 94, 355, 442  
 NF- $\kappa$ B, 65, 163, 168, 281, 283, 322, 341  
 non-Hodgkin lymphoma (NHL), 22, 25, 39, 40, 46, 61, 68, 69, 70, 72, 82, 84, 93, 102, 113, 128, 135, 146, 148, 164, 176, 187, 188, 189, 203, 219, 223, 225, 243, 266, 290, 296, 302, 306, 308, 348, 353, 354, 356, 357, 358, 360, 372, 380, 384, 386, 390, 414, 424, 428, 439, 441, 449, 452, 474, 478, 479, 489, 492, 495, 506, 508, 512, 542, 546, 554, 556, 570  
 non-MALT marginal zone lymphomas, 203  
 Notch pathway, 52, 258  
 obinutuzumab, 56, 131, 547, 561  
 ofatumumab, 421, 553  
 P53, 10, 11, 26, 54, 59, 116, 258, 464, 522  
 PAX5, 156  
 pentostatin, 263  
 performance status, 239, 249  
 peripheral B-cell lymphomas, 174  
 peripheral blood stem cell (PBSC), 507  
 peripheral T-cell lymphomas (PTCL), 2, 20, 41, 95, 118, 138, 151, 153, 185, 232, 234, 236, 238, 265, 301, 444, 445, 446, 447, 448, 450, 453, 499, 564, 565  
 PI3K/AKT/mTOR, 38, 66, 68, 110, 139, 145, 279, 294, 295, 296, 297, 530, 532, 534, 535, 551, 553, 554  
 positron emission tomography (PET), 14, 15, 16, 18, 19, 97, 123, 126, 128, 160, 192, 210, 255, 270, 271, 272, 273, 274, 275, 335, 399, 433, 456, 475, 486, 487, 489, 491, 492, 493, 494, 495, 496, 497, 498, 499, 501, 503, 504, 505, 512  
 post-transplant lymphoproliferative disorders (PTLDs), 216, 366, 570  
 pralatrexate, 539  
 primary CNS lymphoma (PCNSL), 43, 44, 45, 46, 168, 244, 245, 246, 247, 248, 249, 310, 437, 438, 439, 440  
 primary mediastinal large B-cell lymphoma (PMLBCL), 75, 97, 133, 240, 241, 242, 272, 399  
 procarbazine, 36  
 prognostic indices, 14, 15, 54, 55, 74, 90, 142, 172, 173, 178, 183, 186, 189, 207, 211, 222, 252, 272, 278, 312, 329, 334, 336, 345, 352, 384, 389, 392, 394, 465, 486, 488, 497  
 proteasome, 28, 30, 113, 150, 301, 472  
 PTL, 217, 364  
 R-ACVBP, 5, 11, 433  
 radioimmunotherapy (RIT), 111, 231, 264, 406, 474, 476, 478, 480, 507  
 R-CHEOP, 212  
 R-CHOP, 4, 5, 11, 14, 16, 27, 69, 84, 88, 120, 121, 123, 131, 194, 206, 212, 213, 214, 218, 278, 331, 333, 334, 343, 371, 375, 380, 385, 387, 389, 392, 397, 410, 412, 414, 426, 433, 452, 485, 495  
 reduced-intensity conditioning regimen (RIC), 25, 112, 268, 510  
 ribavirine, 363  
 Richter's syndrome (RS), 52, 167, 261  
 rituximab, 7, 37, 45, 56, 63, 68, 84, 98, 100, 102, 103, 104, 105, 106, 119, 121, 131, 135, 136, 137, 149, 150, 186, 191, 193, 194, 195, 196, 198, 199, 207, 208, 209, 215, 217, 218, 220, 223, 230, 247, 248, 251, 260, 285, 289, 292, 298, 300, 343, 347, 350, 358, 367, 370, 373, 374, 375, 377, 378, 379, 383, 397, 399, 401, 413, 420, 436, 440, 468, 469, 470, 492, 529, 532, 536, 547, 549, 552, 554, 555, 557, 559, 560, 561, 562, 563, 570  
 R-MACOP-B, 97  
 romidepsin (RD), 539, 564  
 salvage treatment, 19, 22, 64, 85, 112, 199, 219, 383, 398, 404, 405, 406, 407, 408, 441, 447, 448, 453, 511, 559, 569  
 SCID, 30  
 small lymphocytic lymphoma (SLL), 145, 465  
 SNP, 74, 183, 211, 347  
 splenic marginal zone lymphoma (SMZL), 71, 114, 165, 174, 203, 315, 341, 368  
 splenomegaly, 227  
 statins, 524  
 SYK, 171, 286, 535, 548, 551  
 T-cell lymphoma (TCL), 29, 30, 38, 99, 152, 154, 155, 184, 185, 235, 237, 283, 294, 340, 445, 449, 515, 539  
 T-cell receptor (TCR), 94, 108, 233  
 T-cells, 156, 176, 189, 294, 302, 349, 472  
 temozolomide, 248  
 temsirolimus, 46, 418, 557  
 thymidine kinase, 343  
 TRAIL, 533  
 VEGF, 336  
 Vinca alkaloids, 531  
 Waldenström's macroglobulinemia (WM), 67, 93, 150, 536  
 Xenotransplant, 115  
 zevalin, 200, 201, 231, 474, 475, 477, 478, 479